EDGAR pro
by EDGAR Online

ACLARIS THERAPEUTICS, INC.

Filed by

BONITA BIOTECH (HK) LTD

FORM SC 13G

(Statement of Ownership)

Filed 11/23/26

Address	701 LEE ROAD
	SUITE 103
	WAYNE, PA, 19087
Telephone	484-324-7933
CIK	0001557746
Symbol	ACRS
SIC Code	2834 - Pharmaceutical Preparations
Industry	Biotechnology & Medical Research
Sector	Healthcare
Fiscal Year	12/31

Powered By EDGAR Online
https://www.edgar-online.com
© Copyright 2026, EDGAR Online LLC, a subsidiary of OTC Markets Group. All Rights Reserved.
Distribution and use of this document restricted under EDGAR Online LLC, a subsidiary of OTC Markets Group, Terms of Use.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Aclaris Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.00001 par value

(Title of Class of Securities)

00461U105

(CUSIP Numbers)

11/18/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

SCHEDULE 13G

CUSIP Number(s):	00461U105

1	**Names of Reporting Persons** Biosion, Inc.
2	**Check the appropriate box if a member of a Group (see instructions)** ☐ (a) ☐ (b)
3	**SEC Use Only**

4	**Citizenship or Place of Organization** CHINA	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	**Sole Voting Power:** 9,519,146.00
	6	**Shared Voting Power:** 0.00
	7	**Sole Dispositive Power:** 9,519,146.00
	8	**Shared Dispositive Power:** 0.00
9	**Aggregate Amount Beneficially Owned by Each Reporting Person** 9,519,146.00	
10	**Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)** ☐	
11	**Percent of class represented by amount in row (9)** 6 %	
12	**Type of Reporting Person (See Instructions)** CO	

Comment for Type of Reporting Person: (1) The value in rows (5) and (7) represents 9,519,146 shares of common stock of record by Bonita Biotech (HK) Limited. Bonita Biotech (HK) Limited is wholly owned by Biosion, Inc.

(2) Percent of class represented by amount in row (9) is calculated based on 158,612,149 issued and outstanding shares of Common Stock of the Issuer as at October 30, 2026, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 5, 2026.

SCHEDULE 13G

CUSIP Number(s):	00461U105

1	**Names of Reporting Persons** Bonita Biotech (HK) Ltd	
2	**Check the appropriate box if a member of a Group (see instructions)** ☐ (a) ☐ (b)	
3	**SEC Use Only**	
4	**Citizenship or Place of Organization** HONG KONG	
Number of Shares Beneficially Owned by Each Reporting	5	**Sole Voting Power:** 9,519,146.00
	6	**Shared Voting Power:** 0.00
	7	**Sole Dispositive Power:** 9,519,146.00

Person With:	**8**	**Shared Dispositive Power:** 0.00
9	**Aggregate Amount Beneficially Owned by Each Reporting Person** 9,519,146.00	
10	**Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)** ☐	
11	**Percent of class represented by amount in row (9)** 6 %	
12	**Type of Reporting Person (See Instructions)** CO	

Comment for Type of Reporting Person: (1) The value in rows (5) and (7) represents 9,519,146 shares of common stock of record by Bonita Biotech (HK) Limited.

(2) Percent of class represented by amount in row (9) is calculated based on 158,612,149 issued and outstanding shares of Common Stock of the Issuer as at October 30, 2026, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 5, 2026.

SCHEDULE 13G

Item 1.

(a) **Name of issuer:**

Aclaris Therapeutics, Inc.

(b) **Address of issuer's principal executive offices:**

701 Lee Road, Suite 103, Wayne, Pennsylvania, 19087

Item 2.

(a) **Name of person filing:**

1. Biosion, Inc.

2. Bonita Biotech (HK) Limited

(b) **Address or principal business office or, if none, residence:**

For all reporting persons:

5th Floor, Building D

3-1 Zhongdan Unit, South Longshan Rd

Jiangbei New District

Nanjing, Jiangsu, China

(c) **Citizenship:**

Biosion, Inc. is established under the laws of the People's Republic of China.

Bonita Biotech (HK) Limited is incorporated under the laws of Hong Kong.

(d) **Title of class of securities:**

Common Stock, $0.00001 par value

(e) **CUSIP No.:**

Item 3. **If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

(a) ☐ **Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);**

(b) ☐ **Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);**

(c) ☐ **Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);**

(d) ☐ **Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);**

(e) ☐ **An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);**

(f) ☐ **An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);**

(g) ☐ **A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);**

(h) ☐ **A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);**

(i) ☐ **A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);**

(j) ☐ **A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:**

(k) ☐ **Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).**

Item 4. **Ownership**

(a) **Amount beneficially owned:**

The information for each reporting person contained in Items 5-9 of the cover pages is incorporated herein by reference.

(b) **Percent of class:**

The information for each reporting person contained in Item 11 of the cover pages is incorporated herein by reference.

(c) **Number of shares as to which the person has:**

(i) Sole power to vote or to direct the vote:

The information for each reporting person contained in Item 5 of the cover pages is incorporated herein by reference.

(ii) Shared power to vote or to direct the vote:

The information for each reporting person contained in Item 6 of the cover pages is incorporated herein by reference.

(iii) Sole power to dispose or to direct the disposition of:

The information for each reporting person contained in Item 7 of the cover pages is incorporated herein by reference.

(iv) Shared power to dispose or to direct the disposition of:

The information for each reporting person contained in Item 8 of the cover pages is incorporated herein by reference.

Item 5. **Ownership of 5 Percent or Less of a Class.**

Not Applicable

Item 6. **Ownership of more than 5 Percent on Behalf of Another Person.**

Not Applicable

Item 7. **Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.**

Not Applicable

Item 8. **Identification and Classification of Members of the Group.**

Not Applicable

Item 9. **Notice of Dissolution of Group.**

Not Applicable

Item 10. **Certifications:**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Biosion, Inc.

Signature: **/s/ MINGJIU CHEN**

Name/Title: **MINGJIU CHEN / CEO**

Date: **11/23/2026**

Bonita Biotech (HK) Ltd

Signature: **/s/ MINGJIU CHEN**

Name/Title: **MINGJIU CHEN / Director**

Date: **11/23/2026**

Exhibit Information: Exhibit 99.1 Joint Filing Agreement

Exhibit 99.1

Joint Filing Agreement

In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree (i) to the joint filing, on behalf of each of them, of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock, par value US$0.00001 per share, of Aclaris Therapeutics, Inc.; and (ii) that this joint filing agreement may be included as an Exhibit to such joint filing. The undersigned acknowledge that each shall be responsible for the timely filing of any amendments to such joint filing and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others.

Biosion, Inc.

Signature: /s/ MINGJIU CHEN
Name/Title: MINGJIU CHEN / CEO

Bonita Biotech (HK) Limited

Signature: /s/ MINGJIU CHEN
Name/Title: MINGJIU CHEN / Director